Treatment benefits patients with thalassaemia and HCV
Thursday, June 29, 2017 - 13:02
in Health & Medicine
Many individuals with the blood disorder thalassaemia also carry the hepatitis C virus (HCV) due to contaminated transfusions before 1990. Due to the co-existence of iron overload (from repeated blood transfusions), these patients are at increased risk of developing liver cancer. A new study indicates that treatment with a combination of sofosbuvir and ledipasvir as a once a day single pill leads to a sustained virological response in 98% of patients with thalassaemia and HCV.